AstraZeneca chief executive Pascal Soriot has expressed happiness over the UK-US deal on NHS pricing, but said his company may still not lift the pause on £200m investment in Cambridge.
He told The Guardian that the recent drug pricing deal was a positive step, but it is not 'sufficient' to revive the research hub project.
Britain’s biggest pharmaceutical company had recently announced £11bn of investments in China, during prime minister Kier Starmer's visit to Beijing.
It had earlier committed to invest $50bn in its US factories and labs by 2030.
AstraZeneca's chief said the company still needed to understand the practical implications of the pharmaceutical deal.
He felt the deal may improve access to a number of medicines for patients, but would not be sufficient for "truly innovative products".
Meanwhile, AstraZeneca has forecast steady sales and profit growth this year.
It is banking on strong demand for cancer drugs and new launches to offset patent losses and pricing pressure.
Soriot hopes the company will reach the target of $80bn in annual sales by 2030.
